POLA1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P04835(POLA1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of POLA1 Antibodies**

POLA1 (DNA Polymerase Alpha 1) is a critical subunit of the DNA polymerase α-primase complex, essential for initiating DNA replication in eukaryotic cells. This enzyme synthesizes short RNA-DNA hybrid primers during the replication of the lagging strand, providing a 3'-OH group for DNA polymerases δ/ε to elongate. POLA1 contains two functional domains: a C-terminal polymerase domain and an N-terminal regulatory region interacting with other replication machinery components.

POLA1 antibodies are valuable tools for studying DNA replication mechanisms, cell cycle regulation, and genome stability. They are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to detect POLA1 expression, localization, and interactions in cellular models. Dysregulation of POLA1 has been linked to diseases, including cancers (e.g., colorectal, breast) and viral infections, where replication stress or aberrant DNA synthesis occurs.

Recent studies highlight POLA1's role in cancer progression, making it a potential therapeutic target. Inhibitors or antibodies targeting POLA1 could disrupt replication in rapidly dividing cancer cells. Additionally, POLA1 autoantibodies have been explored as biomarkers in autoimmune disorders.

Commercial POLA1 antibodies are typically validated for specificity against the human protein (∼180 kDa), with applications in basic research and drug development. However, variability in antibody performance (e.g., cross-reactivity) necessitates careful validation for experimental consistency. Overall, POLA1 antibodies remain pivotal in elucidating DNA replication biology and its disease-related implications.